• Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit

  2026-08-04

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit addresses the challenge of high-resolution separation for proteins and peptides in the 1–10 kDa range, where conventional Tris-glycine SDS-PAGE systems show limited efficacy. It is intended strictly for scientific research and not suitable for diagnostic or clinical applications.

• Hoechst 33258: Advanced DNA Staining for Tumor pH Analysis

  2026-08-04

  Hoechst 33258 stands out as a bis-benzimide DNA stain that empowers high-sensitivity DNA visualization in both live and fixed cells, even within the challenging context of tumor pH modulation. This guide translates cutting-edge reference findings into practical protocols and troubleshooting strategies for researchers seeking to couple DNA staining with dynamic tumor microenvironment assays.

• RESTRICT-seq Identifies KAT6A as a Key Epigenetic Dependency

  2026-08-03

  The reference study introduces RESTRICT-seq, a time-gated CRISPR screening platform that enables discovery of temporal epigenetic dependencies in squamous cell carcinoma (SCC) resistance. By revealing KAT6A’s central role in oncogene-induced senescence and resistance, the work offers actionable insights for targeted epigenetic inhibition in cancer biology.

• Dorsomorphin 2HCl: Applied AMPK Inhibition for Metabolic Res

  2026-08-03

  Dorsomorphin 2HCl empowers researchers to dissect AMPK and BMP pathways with precision, offering robust control over metabolic, osteogenic, and iron homeostasis models. This article translates recent preclinical breakthroughs into actionable protocols, troubleshooting strategies, and advanced applications for bench scientists.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Next-Gen Reporter f

  2026-08-02

  Explore how Firefly Luciferase mRNA (ARCA, 5-moUTP) empowers advanced gene expression and cell viability assays with translational efficiency and immune evasion. This in-depth analysis uniquely focuses on the intersection of mRNA chemistry, nanoparticle delivery, and assay optimization.

• YC-1 in Translational Oncology: Mechanism, Impact, and Strat

  2026-08-01

  Explore how YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol advances translational cancer research by bridging mechanistic HIF-1α inhibition with real-world assay design. This article synthesizes cutting-edge mechanistic studies, practical workflow guidance, and competitive insights, offering actionable strategies for researchers seeking to optimize cancer biology experiments and understand the translational promise of YC-1. Strategic discussion differentiates this analysis from basic product descriptions and standard literature reviews.

• Netarsudil (AR-13324): Redefining siRNA Codelivery in Transl

  2026-07-31

  Explore the mechanistic and strategic dimensions of Netarsudil (AR-13324) as a Rho kinase inhibitor and predictive siRNA codelivery agent. This article bridges cytoskeletal modulation with next-generation nanoparticle therapeutics, providing translational researchers with actionable insights and rigorous protocol guidance.

• Rucaparib (AG-014699): Workflow Enhancements in DNA Damage R

  2026-07-31

  Rucaparib (AG-014699) from APExBIO is redefining DNA damage response research by enabling precise radiosensitization and selective DNA repair inhibition, especially in PTEN-deficient and ETS fusion-expressing prostate cancer models. This article details robust experimental workflows, protocol enhancements, and troubleshooting strategies, while translating novel mechanistic insights from recent high-impact studies into actionable laboratory guidance.

• LncRNA FAISL Inhibits Calpain-2–FAK Cleavage in TNBC Progres

  2026-07-30

  The referenced study reveals that lncRNA FAISL drives triple negative breast cancer (TNBC) progression by safeguarding FAK protein from calpain-2–mediated proteolysis. This discovery elucidates a novel regulatory axis in cell adhesion and metastasis, offering new directions for targeted intervention in aggressive breast cancers.

• Epacadostat (INCB024360) in Immuno-Oncology Assays: Applied

  2026-07-30

  Epacadostat (INCB024360) empowers researchers to dissect tumor immune evasion with nanomolar precision in standardized whole-blood and cell-based immunometabolic assays. Explore robust workflows, practical protocol enhancements, and troubleshooting strategies to maximize reproducibility and immune modulation insight.

• Dimetridazole: Applied Workflows and Troubleshooting in Biof

  2026-07-29

  Dimetridazole (1,2-Dimethyl-5-nitroimidazole) is uniquely positioned as both a potent quorum sensing inhibitor for antimicrobial resistance research and a sensitive analyte for electrochemical biosensing. This article delivers concrete workflows, troubleshooting advice, and comparative insights to unlock the full experimental value of Dimetridazole from APExBIO.

• Nicotine Signaling and CKD Progression: Mechanistic Insights

  2026-07-29

  This article reviews the mechanistic findings of Jain and Jaimes (2013), who established a direct role for nicotine signaling in accelerating chronic kidney disease (CKD) progression in smokers. Their synthesis of clinical and experimental evidence highlights non-neuronal nicotinic acetylcholine receptor involvement, advancing our understanding of CKD pathogenesis in the context of tobacco exposure.

• Tetrahydromagnolol: Applied Workflows for Peripheral CB2 Ago

  2026-07-28

  Tetrahydromagnolol stands out as a highly selective peripheral CB2 receptor agonist, enabling advanced cannabinoid receptor and anti-inflammatory research with reliable performance. Learn how to optimize protocols, troubleshoot common issues, and deploy this compound in cutting-edge GPCR and metastasis studies.

• N-octanoyl-L-Homoserine Lactone: Pathogenicity & Assay Workf

  2026-07-28

  N-octanoyl-L-Homoserine lactone (C8-HSL) empowers researchers to dissect bacterial quorum sensing and its direct effects on host cell behavior, including cancer progression. This guide delivers actionable workflows, troubleshooting tips, and data-driven insights to optimize microbial pathogenicity research and translational studies.

• Mubritinib–HSA Binding: Implications for Drug Bioavailabilit

  2026-07-27

  This study clarifies how Mubritinib, an electron transport chain inhibitor, binds to human serum albumin (HSA), revealing a moderate affinity and detailed interaction profile. The findings provide mechanistic insight into drug distribution, bioavailability, and protein functional modulation, informing translational research on drug–protein interactions.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page